Welcome reception

Introduction & Meeting Objectives
John Gribben

Session 1:  T-cell Leukemia/Lymphoma
Chairs: Laurence de Leval & Francine Foss

Overview Lecture: LGL Leukemia – current treatments and perspectives: TBC

• T-PLL: Advances and Perspectives: TBC
• HTLV-1 ATLL: Contemporary Outcomes: Lucy Cook
• Current and future treatment approaches in T-cell lymphoma: Francine Foss
• AUTO4 (TRBC1 directed autologous CAR-T) in TRBC1-positive PTCL: Kate Cwynarski

Panel Discussion

Break

Session 2:  Evolving frontline immune-chemotherapy for MCL and the impact on survival outcomes
Chairs: Stephen Ansell & Elaine Jaffe

• How do genetics and pathology of MCL guide treatment decisions? TBC
• Has frontline therapy for MCL changed from intensive chemo-based to targeted small molecule -based?: John Kuruvilla
• Should frontline treatment for MCL be ‘chemo-free’ – where do cellular therapies fit in?: TBC
• Has maintenance therapy replaced ASCT in MCL?: Michael Williams
• New strategies to manage relapsed MCL: Caron Jacobson

Panel Discussion: Remaining gaps and perspectives

Session 3: Keynote address
Chair & Introduction: Carmelo Carlo-Stella

Modelling the crosstalk between malignant B cells and their microenvironment in B-cell lymphomas: challenges and opportunities: TBC

Panel Discussion

Lunch

Session 4: Novel Therapies
Chairs: John Gribben & Laurie Sehn  

• Novel drug development: an industry perspective: Simon Rule (Astra Zeneca)

Industry Panel Discussion

ADCs:

• Polatuzumab vedotin: Laurie Sehn
• Zilovertamab: Sven De Vos
• Loncastuximab Tesirine: Paolo Caimi
• Camidanlumab: Andrew Davies
• Emerging ADCs with novel targets: Juan Pablo Alderuccio
• DBCL: Alex Herrera

Panel Discussion

Break

Session 5: Debate
Chairs:  Anna Sureda & Catherine Bollard

“Should CD19 CAR-T cell treatment be selected by age and co-morbidity?”

Jason Westin (NO)

TBC (YES)

Panel Discussion

Day 1 wrap-up

Session 6: Expanding the CAR platform for NHL
Chairs: David Maloney & TBC  

• Tis-a-cel: TBC
• Axi-cel: Sattva Neelapu
• Liso-cel: David Maloney
• CD20 CAR-T (MB-106): TBC
• Rapcabtagene: TBC
• CB-010: TBC

Panel Discussion (15 min)

• Development of CAR-T platforms for T-cell lymphomas: Laquisa Hill
• CAR-T vs Auto HCT in first relapse – is auto-HCT dead?: Jason Westin
• Strategies to minimize toxicity of CAR-T cell treatment: Caron Jacobson
• Allogeneic CAR-T cells: Is there a strategy moving forward?:  TBC
• CAR-T for CLL.  Where do we stand? Who and when do we treat?: Tanya Siddiqi

Panel Discussion: CAR-T in the real-world setting

 

Break

Session 7: Special Topic

Introduction: Riccardo Dalla-Favera

The germinal center in the pathogenesis of B cell lymphomas: Laura Pasqualucci

Panel Discussion

Session 8: Novel Therapies part 2
Chairs:  Laurie Sehn & TBC

• LYSA in a nutshell: TBC

BTK Inhibitors:

• Is there till a role for ibrutinib?: TBC
• Zanubrutinib: Pier Luigi Zinzani
• Acalabrutinib: Stephen Ansell
• Pirtobrutinib: TBC

Panel Discussion

BTK Degraders:

• NX-2127 & NX-5948: Alexey Danilov
• NX-5948: TBC

BCL-2 inhibitors:

• BGB-11417 (sonrotoclax): TBC
• Novel venetoclax combinations: Tanya Siddiqi
• ViPOR regimen in DLBCL: Jordan Goldstein
  Panel Discussion

Lunch

Session 9: Bispecific antibodies for NHL
Chairs: Martin Hutchings & Marion Subklewe

CD3/CD20 bispecifics and their quest for ideal partners

• Glofitamab: Martin Hutchings
• Mosunetuzumab: TBC
• Odronextamab: Stephen Ansell
• Epcoritamab: Martin Hutchings
• Plamotamab: TBC

Panel Discussion

Break

Bispecific and trispecifics with other formats and targets
Chairs: TBC

• Imvotamab: TBC
• TNB 486: TBC
• Other bi- and tri-specific antibodies in early development: Marion Subklewe

Panel Discussion: Future directions  

Final Meeting Summary & Conclusions:
iwNHL Committee